Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly for molecular glue therapeutics.

A steady supply of weight-loss drugs Wegovy and Mounjaro has helped lift Eucalyptus’ revenue from $78 million to $121 million ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

We recently published an article titled Jim Cramer Discusses These 10 Stocks & Says Bitcoin Created "Froth" In The Market. In ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...